{"id":"https://openalex.org/W2912373397","doi":null,"title":"Characterization of CAT-8015: A Pseudomonas exotoxin based immunotoxin for the treatment of CD22-related hematological malignancies","display_name":"Characterization of CAT-8015: A Pseudomonas exotoxin based immunotoxin for the treatment of CD22-related hematological malignancies","publication_year":2006,"publication_date":"2006-04-15","ids":{"openalex":"https://openalex.org/W2912373397","mag":"2912373397"},"language":"en","primary_location":{"id":"mag:2912373397","doi":null,"is_oa":false,"landing_page_url":"https://cancerres.aacrjournals.org/content/66/8_Supplement/877.4","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110185766","display_name":"Ralph F. Alderson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ralph Alderson","raw_affiliation_strings":["Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077111567","display_name":"Enrique Escand\u00f3n","orcid":"https://orcid.org/0000-0002-2297-969X","observed_orcids":["https://orcid.org/0000-0002-2297-969X"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Enrique Escand\u00f3n","raw_affiliation_strings":["Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053700867","display_name":"Tianling Chen","orcid":"https://orcid.org/0000-0002-2721-0636","observed_orcids":["https://orcid.org/0000-0002-2721-0636"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tianling Chen","raw_affiliation_strings":["Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018453715","display_name":"Peter Yeung","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter Yeung","raw_affiliation_strings":["Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037275731","display_name":"Douglas Hodges","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas Hodges","raw_affiliation_strings":["Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Wei Geng","orcid":"https://orcid.org/0009-0009-9231-5547","observed_orcids":["https://orcid.org/0009-0009-9231-5547"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wei Geng","raw_affiliation_strings":["Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA"],"raw_orcid":"https://orcid.org/0009-0009-9231-5547","affiliations":[{"raw_affiliation_string":"Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088331887","display_name":"David J. FitzGerald","orcid":"https://orcid.org/0000-0002-6589-0126","observed_orcids":["https://orcid.org/0000-0002-6589-0126"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Fitzgerald","raw_affiliation_strings":["Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA"],"raw_orcid":"https://orcid.org/0000-0002-6589-0126","affiliations":[{"raw_affiliation_string":"Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025737516","display_name":"Robert J. Kreitman","orcid":"https://orcid.org/0000-0001-5141-1844","observed_orcids":["https://orcid.org/0000-0001-5141-1844"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert J. Kreitman","raw_affiliation_strings":["Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA"],"raw_orcid":"https://orcid.org/0000-0001-5141-1844","affiliations":[{"raw_affiliation_string":"Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056573254","display_name":"Ira H Pastan","orcid":"https://orcid.org/0000-0002-9223-0270","observed_orcids":["https://orcid.org/0000-0002-9223-0270"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ira Pastan","raw_affiliation_strings":["Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA"],"raw_orcid":"https://orcid.org/0000-0002-9223-0270","affiliations":[{"raw_affiliation_string":"Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043247560","display_name":"Judy A. Fox","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Judy A. Fox","raw_affiliation_strings":["Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cambridge Antibody Technology Inc., Palo Alto, CA, Genencor, Inc, Palo Alto, CA, National Cancer Institute, Bethesda, MD, Genencor Inc., Palo Alto, CA","institution_ids":["https://openalex.org/I4210140884"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210140884"],"apc_list":null,"apc_paid":null,"fwci":0.113,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.53055556,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"66","issue":null,"first_page":"877","last_page":"877"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immunotoxins","display_name":"immunotoxins","score":0.824999988079071},{"id":"https://openalex.org/keywords/pseudomonas-exotoxin-a","display_name":"Pseudomonas exotoxin A","score":0.9399999976158142},{"id":"https://openalex.org/keywords/pe38","display_name":"PE38","score":0.8270000219345093},{"id":"https://openalex.org/keywords/cd22","display_name":"CD22","score":0.9309999942779541},{"id":"https://openalex.org/keywords/b-cell-malignancies","display_name":"B-cell malignancies","score":0.7289999723434448},{"id":"https://openalex.org/keywords/burkitt-lymphoma","display_name":"Burkitt lymphoma","score":0.9610000252723694},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.6869999766349792},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8360000252723694},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.6520000100135803},{"id":"https://openalex.org/keywords/cytotoxicity","display_name":"cytotoxicity","score":0.5630000233650208},{"id":"https://openalex.org/keywords/adp-ribosylation","display_name":"ADP-ribosylation","score":0.6980000138282776},{"id":"https://openalex.org/keywords/tumor-shrinkage","display_name":"tumor shrinkage","score":0.3370000123977661}],"concepts":[{"id":"https://openalex.org/C115085202","wikidata":"https://www.wikidata.org/wiki/Q425665","display_name":"Immunotoxin","level":4,"score":0.9879696369171143},{"id":"https://openalex.org/C182179738","wikidata":"https://www.wikidata.org/wiki/Q907386","display_name":"Pseudomonas exotoxin","level":4,"score":0.9414339065551758},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.6180179715156555},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.5901297926902771},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5644457340240479},{"id":"https://openalex.org/C111700020","wikidata":"https://www.wikidata.org/wiki/Q5009798","display_name":"CD22","level":4,"score":0.5575131177902222},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5313513875007629},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.5191634893417358},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4991445541381836},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.49082955718040466},{"id":"https://openalex.org/C2778723905","wikidata":"https://www.wikidata.org/wiki/Q408649","display_name":"Exotoxin","level":3,"score":0.4674355089664459},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.4670613706111908},{"id":"https://openalex.org/C53227056","wikidata":"https://www.wikidata.org/wiki/Q189152","display_name":"Viability assay","level":3,"score":0.4153823256492615},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4022536277770996},{"id":"https://openalex.org/C2777367657","wikidata":"https://www.wikidata.org/wiki/Q184651","display_name":"Toxin","level":2,"score":0.3361778259277344},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2759544253349304},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.26418912410736084},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.2111320197582245},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2912373397","doi":null,"is_oa":false,"landing_page_url":"https://cancerres.aacrjournals.org/content/66/8_Supplement/877.4","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":null,"raw_source_name":"Cancer Research","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.7900000214576721}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2583926568","https://openalex.org/W2169000897","https://openalex.org/W2165800290","https://openalex.org/W2164337721","https://openalex.org/W85464595","https://openalex.org/W2000568282","https://openalex.org/W1548735291","https://openalex.org/W3148036136","https://openalex.org/W2408363900","https://openalex.org/W2279929035","https://openalex.org/W2568488427","https://openalex.org/W2566147693","https://openalex.org/W2981144974","https://openalex.org/W2186867915","https://openalex.org/W2324594876","https://openalex.org/W157720121","https://openalex.org/W2064250310","https://openalex.org/W2411479157","https://openalex.org/W2048245638","https://openalex.org/W2909827784"],"abstract_inverted_index":{"3728":[0],"Immunotoxins":[2],"are":[3,10],"a":[4,15,20,28,80,127,151,192,225,236,245,254,295,307,354,364,376],"class":[5],"of":[6,14,33,39,51,59,87,93,130,187,214,227,274,357,373],"anti-cancer":[7],"therapies":[8],"that":[9,112,252,369,383],"hybrid":[11],"proteins":[12],"composed":[13],"tumor-targeting":[16],"monoclonal":[17,43],"antibody":[18],"and":[19,45,48,71,84,142,145,163,166,173,179,259,306],"cell-killing":[21],"toxin":[22],"moiety.":[23],"CAT-8015":[24,60,136,188,286,362],"(formerly":[25,291],"HA22)":[26],"is":[27,363],"second":[29],"generation":[30],"immunotoxin":[31,116,216,368],"consisting":[32],"disulfide":[34],"bond":[35],"stabilized":[36],"Fv":[37],"fragments":[38],"RFB4,":[40],"an":[41,85,325],"anti-CD22":[42],"antibody,":[44],"the":[46,66,99,115,146,167,197,205,215,321,388],"translocating":[47],"ADP-ribosylating":[49],"domains":[50],"Pseudomonas":[52],"exotoxin":[53],"A":[54],"(PE38).":[55],"The":[56,91,154,182],"biological":[57],"activity":[58,186],"was":[61,103,123,189,282,312],"examined":[62,190],"in":[63,95,139,176,183,191,235,248,309,352,375],"vitro":[64],"on":[65],"EHEB,":[67],"CA46,":[68],"Mec1,":[69],"Daudi":[70],"JD38":[72,330],"B-cell":[73],"lines":[74,102],"using":[75,150,196],"two":[76],"different":[77],"cytotoxicity":[78],"assays;":[79],"cell":[81,101,131,201],"viability-based":[82],"assay":[83],"inhibition":[86,356],"protein":[88],"synthesis-based":[89],"assay.":[90],"range":[92],"IC50s":[94],"both":[96],"assays":[97],"for":[98,117,224,338],"various":[100],"0.1":[104],"-":[105,316],"10":[106],"ng/ml.":[107],"Time":[108],"course":[109],"studies":[110,134],"demonstrated":[111],"exposure":[113],"to":[114,125,159,278],"as":[118,120,301,303,346,348],"little":[119],"4":[121],"hr":[122,165,222],"sufficient":[124],"induce":[126],"significant":[128],"amount":[129],"killing.":[132],"Pharmacokinetic":[133],"with":[135,231,264,342],"were":[137,148,157,170,217,262,332,384],"conducted":[138],"mice,":[140,177],"rats":[141,178],"cynomolgus":[143],"monkeys":[144],"data":[147],"analyzed":[149],"compartmental":[152],"model.":[153],"t1/2":[155],"values":[156,169],"calculated":[158],"be":[160],"0.42,":[161],"0.61":[162],"0.78":[164],"Vss":[168],"1.37,":[171],"10.6":[172],"123.1":[174],"ml":[175],"monkeys,":[180],"respectively.":[181],"vivo":[184],"anti-tumor":[185],"subcutaneous":[193],"tumor":[194,207,249,310,358],"model":[195,380],"CD22-expressing":[198],"Burkitt\u2019s":[199],"lymphoma":[200,379],"line":[202],"JD38.":[203],"When":[204],"average":[206],"volume":[208,250],"reached":[209,253],"100-200":[210],"mm3,":[211,281],"increasing":[212],"doses":[213,265,300,322,345,382],"administered":[218,333],"intravenously":[219],"at":[220,299,319,344,381],"48":[221],"intervals":[223],"total":[226],"three":[228],"doses.":[229,340],"Treatment":[230,341],"12.5":[232],"\u03bcg/kg":[233,305],"resulted":[234,351],"cytostatic":[237,296],"response.":[238],"At":[239],"higher":[240],"doses,":[241],"\u2265":[242,266],"25":[243],"\u03bcg/kg,":[244],"rapid":[246,272],"reduction":[247],"occurred":[251],"nadir":[255],"within":[256,314],"7":[257],"days,":[258],"complete":[260,371],"remissions":[261],"achieved":[263,284],"75":[267],"\u03bcg/kg.":[268],"In":[269,288,360],"additional":[270,326],"experiments,":[271],"shrinkage":[273],"larger":[275],"tumors,":[276],"up":[277],"approximately":[279],"800":[280],"also":[283],"following":[285],"administration.":[287],"contrast,":[289],"CAT-3888":[290],"BL22)":[292],"administration":[293],"induced":[294,370],"response":[297],"even":[298],"high":[302,347],"150":[304],"rebound":[308],"growth":[311],"observed":[313],"2":[315],"3":[317,339],"weeks":[318],"all":[320],"tested.":[323],"As":[324],"comparison,":[327],"animals":[328],"bearing":[329],"tumors":[331,374],"rituximab":[334,343],"every":[335],"four":[336],"days":[337],"5":[349],"mg/kg":[350],"only":[353],"transitory":[355],"growth.":[359],"summary,":[361],"highly":[365],"efficacious":[366],"CD22-directed":[367],"remission":[372],"mouse":[377],"xenograft":[378],"well":[385],"tolerated":[386],"by":[387],"mice.":[389]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":4}],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2025-10-10T00:00:00"}